Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-ketoanalogues and essential amino acids
- Development stage
- Unknown
- Lead developer
- Septalyst Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SEPTASTERIL DS is a pharmaceutical combination of alpha-ketoanalogues and essential amino acids developed by Septalyst Lifesciences for the management of chronic kidney disease (CKD). It is specifically indicated for patients with a glomerular filtration rate (GFR) between 5 and 15 mL/min to treat and prevent protein metabolism disorders. The formulation works by providing nitrogen-free analogues of essential amino acids that undergo transamination in the body, utilizing nitrogen from non-essential amino acids to form the corresponding essential amino acids. This process effectively reduces the production of urea and other nitrogenous waste products, allowing patients to maintain nutritional status while adhering to a low-protein diet, thereby slowing the progression of renal failure.
- Brand names
- SEPTASTERIL DSSeptasteril
- Other names
- alpha-ketoanalogues of amino acids
02
Targets
AST (Glutamate oxaloacetate transaminase 1)
Beyond the preview
Go deeper on alpha-ketoanalogues and essential amino acids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-ketoanalogues and essential amino acids.